Formulary management in the Department of Defense

Journal of Managed Care Pharmacy

Volumn 15, Issue 2, 2009, Pages 133-146

  Trice, Shana ^a   Devine, Joshua ^b   Mistry, Harsha ^a   Moore, Eugene ^a   Linton, Andrea ^c  

^a DoD TRICARE Management Activity   (United States)

^b DoD PEC   (United States)

^c Off of the Assistant Sec of Def Hlth Aff Hlth Prog Analysts/Eval   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 AMINOBUTYRIC ACID DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIGLAUCOMA AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CONTRACEPTIVE AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH PROMOTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC SEDATIVE AGENT; KETOLIDE; LEUKOTRIENE DERIVATIVE; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; NARCOTIC ANALGESIC AGENT; PHOSPHODIESTERASE V INHIBITOR; PROTON PUMP INHIBITOR; UNINDEXED DRUG; URINARY TRACT AGENT;

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; MILITARY PHENOMENA; PHARMACY; PHARMACY AND THERAPEUTICS COMMITTEE; PRESCRIPTION; PRIVATE HEALTH INSURANCE; SOLDIER; UNITED STATES;

EID: 63349102017     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.2.133     Document Type: Article

References (44)

1. Promoting Quality and Efficient Health Care in Federal Government Administered or Sponsored Health Care Programs. Presidential Executive Order No. 13410, 3 C.F.R. Available at: http://edocket.access.gpo.gov/ cfr_2007/janqtr/pdf/3CFR13410.pdf. Accessed September 8, 2008.
2. U.S. Code of Federal Regulations. Civilian health and medical program of the Uniformed Services: pharmacy benefits program (32 C.F.R. Sect. 199.21). Available at: http://edocket.access.gpo.gov/cfr_2007/julqtr/ 32cfr199.21.htm. Accessed September 1, 2008.
3. Department of Defense Task Force on the Future of Military Health Care. Final report (December 2007). Available at: www.dodfuturehealthcare.net. Accessed September 1, 2008.
4. TRICARE Management Activity. TRICARE Pharmacy web site. Available at: www.tricare.mil/pharmacy. Accessed January 13, 2008.
5. Health Affairs Policy 04-032. TRICARE Pharmacy Benefit Program Formulary Management (December 22, 2004). Available at: www.ha.osd.mil/policies/ 2004/04-032.pdf. Accessed September 1, 2008.
6. Clarification to Health Affairs Policy 04-032. TRICARE Pharmacy Benefit Program Formulary Management (March 22, 2005). Available at: www.ha.osd.mil/policies/2004/04-032_clarification.pdf. Accessed September 1, 2008.
7. MTF Formulary Management for Angiotensin Receptor Blockers (ARBs). Available at: www.pec.ha.osd.mil/MTF/ ARB_MTF_Formulary_Management_Aug07.pdf. Accessed December 10, 2008.
8. MTF Formulary Management for Proton Pump Inhibitors (PPIs). Available at: www.pec.ha.osd.mil/MTF/PPI_MTF_Formulary_Managernent_Jul07.pdf. Accessed December 10, 2008.
9. DoD Pharmacoeconomic Center. Future meetings of the DoD P&T Committee. Available at: www.pec.ha.osd.mil/PT_Committee.htm. Accessed September 1, 2008.
10. Oxford Centre for Evidence-based Medicine. Levels of evidence (May 2001). Available at: www.cebm.net. (EBM Tools). Accessed January 12, 2008.
11. The Cochrane Collaboration. Home page. Available at www.cochrane.org. Accessed September 1, 2008.
12. Drug Effectiveness Review Project. Home page. Available at: www.ohsu.edu/ ohsuedu/research/policycenter/DERP/index.cfm. Accessed September 1, 2008.
13. Agency for Healthcare Research and Quality. Technology Assessments. Available at: www.ahrq.gov/clinic/techix.htm. Accessed September 1, 2008.
14. National Institute for Clinical Excellence. Published Appraisals. Available at: www.nice.org.uk/Guidance/TA/Published. Accessed September 1, 2008.
15. Canadian Agency for Drugs and Technology in Health. Health Technology Assessment. Available at: www.cadth.ca/index.php/en/hta. Accessed September 1, 2008.
16. Pettiti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. Oxford: Oxford University Press; 2000: 264-71.
17. Fullerton DS, Atherly DS. Formulary development at Regence BlueShield - a formula for success. Value Health. 2002;5(4):297-300.
18. Sullivan SD, Lyles A, Luce B, Grigar J. AMCP guidance for submission of clinical economic evaluation to support formulary listing in U.S. health plans and pharmacy benefits management organizations. J Manag Care Pharm. 2001;7(4):272-82. Available at: www.amcp.org/data/jmcp/ Research-272-282.pdf.
19. Foundation for Managed Care Pharmacy. The AMCP format for formulary submissions. Version 2.1: a format for the submission of clinical and economic evaluation data in support of formulary consideration by managed health care systems in the United States. Alexandria, VA: Academy of Managed Care Pharmacy; 2005.
20. Drummond MF, Sculpher MJ, Torrance GW, O'Brian BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd Ed. Oxford: Oxford University Press; 2005.
21. Minutes and Decision Paper on the DoD Pharmacy and Therapeutics Committee Meeting - 13 June 2008 - Signed 27 August 2008. Available at: www.tricare.mil/pharmacy/PT_Cmte/defaurt.htm. Accessed December 10, 2008.
22. The Congress of the United States. Congressional Budget Office. Prices for brand-name drugs under selected federal programs (June 2005). Available at: www.cbo.gov/ftpdocs/64xx/doc6481/06-16-PrescriptDrug.pdf. Accessed September 1, 2008.
23. U.S. Code. Limitation on prices of drugs procured by Department and certain other federal agencies. Title 38 U.S.C. (Veteran's Benefits), Part VI, Chap. 81, Subchap. II, Sect 8126. Available at: www.gpoaccess.gov/uscode/index.html (search for "38USC8126"). Accessed January 13, 2008.
24. Veterans Health Care Act of 1992, Pub. L. No. 102-585, Sect. 603. Available at: www.hrsa.gov/opa/pl102585.htm. Accessed January 13, 2008.
25. Department of Veterans Affairs National Acquisition Center. Federal supply schedule service - pharmaceuticals. Available at: wwwl.va.gov/ oamm/oa/nac/fsss/pharmfss.cfm. Accessed January 13, 2008.
26. Federal Register Online. Civilian health and medical program of the Uniformed Services/Inclusion of TRICARE Retail Pharmacy Program in Federal Procurement of Pharmaceuticals (July 25, 2008). 2008:73(144):43394-97. Available at: http://edocket.access.gpo.gov/2008/ E8-17024.htm. Accessed September 1, 2008.
27. TRICARE Management Activity. Program information for pharmaceutical manufacturers. Available at: www.tricare.mil/pharm_mfg/default.cfm. Accessed September 12, 2008.
28. United States Government Accountability Office. DoD pharmacy benefits program: reduced pharmacy costs resulting from the Uniform Formulary and manufacturer rebates; October 31, 2007. Report: GAO-08-172R. Available at: www.gao.gov/new.items/d08172r.pdf. Accessed February 28, 2008.
29. Russell LB, Siegel JE, Daniels N, Gold MR, Luce BR, Mandelblatt JS. Cost-effectiveness analysis as a guide to resource allocation in health: roles and limitations. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996:3-24.
30. Mauskopf J, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoeconomics Outcomes Res. 2005;5(1):65-79.
31. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479-500.
32. Minutes and Decision Paper of the DoD Pharmacy and Therapeutics Committee Meeting - 15-16 May 2007 - Signed 24 July 2007. Available at: www.tricare.mil/pharmacy/PT_Cmte/default.htm. Accessed December 10, 2008.
33. Matza LS, Secnik K, Rentz AM, et al. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report. Qual Life Res. 2005;14:735-47.
34. Secnik K, Matza L, Cottrell S, Edgell E, Tilden D, Mannix S. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med Decis Making. 2005;25:56-70.
35. TRICARE Management Activity. TRICARE Pharmacy: Uniform Formulary Medical Necessity Criteria for Proton Pump Inhibitors. Available at: www.tricare.mil/pharmacy/ppi_mn_criteria.cfm. Accessed September 1, 2008.
36. TRICARE Management Activity. Uniform Formulary Beneficiary Advisory Panel Charter (July 27, 2006). Available at: www.tricare.mil/pharmacy/ bap/Signed%20Charter%20-%20July%202008.pdf. Accessed December 12, 2008.
37. TRICARE Management Activity. Homepage of the Uniform Formulary Beneficiary Advisory Panel. Available at: www.tricare.mil/pharmacy/BAP/. Accessed January 13, 2008.
38. Library of Congress THOMAS database. Summary: national defense authorization act for fiscal year 2008 (U.S. Public Law 110-181), section 703. Available at: http://purl.access.gpo.gov/GPO/LPS96466. Accessed January 21, 2009.
39. Shrank WH, Young HN, Ettner SL, Glassman P, Asch SM, Kravitz RL. Do the incentives in 3-tier pharmacy benefit plans operate as intended? Results from a physician leadership survey. Am J Manag Care. 2005; 11:16-22.
40. National Council for Prescription Drug Programs. NCPDP ePrescribing Fact Sheet. Available at: www.ncpdp.org/eprescribing.asp. Accessed December 10, 2008.
41. Department of Defense awards U.S. armed forces formulary management contract to Zynchros, Inc. Available at: www.zynchros.com/news-events/ news/2007/16oct-dod.asp. Accessed September 8, 2008.
42. TRICARE Management Activity. DoD Formulary Search Tool. Available at: www.tricareformularysearch.org/dod/medicationcenter/default.aspx. Accessed December 10, 2008.
43. Fairman KA, Motheral BR. Do decision-analytic models identify cost-effective treatments? A retrospective look at Helicobacter pylori eradication. J Manag Care Pharm. 2003;9(5):430-40. Available at: www.amcp.org/data/jmcp/Formulary%20Management-430-440.pdf.
44. Cox ER, Motheral B, Mager D. Verification of a decision analytic model assumption using real-world practice data: implications for the cost-effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s). Am J Manag Care. 2003;9(12):785-94.